A panel discussion regarding the underdiagnosis and burden of migraine attacks on patients and the rationale for educating the community about signs and symptoms.

Amy R. Dunleavy, PharmD, highlights various drug therapies used for the acute treatment of migraine and provides recommendations for appropriate use.

Timothy Smith, MD, RPh, FACP, AQH, describes goals of therapy for the acute treatment of migraine and reacts to current treatment limitations associated with available drug therapies.

Special considerations for counseling patients and prescribing lasmiditan, a targeted 5-HT1F therapy approved as acute migraine treatment.

Jennifer L. Mazan, PharmD, describes the role of CGRP antagonists as acute migraine treatment and shares considerations for selecting and using these therapies.

Preventive therapies available for patients who require migraine prophylaxis and factors that impact treatment selection.

Factors that need to be considered when determining patient candidacy for over-the-counter herbal products and nutritional supplements available as preventive therapy for migraine and recommendations for educating patients about their use.

An overview of CGRP antagonists approved as preventive therapy for migraine and recommendations for appropriate dosing and administration to patients.

What community pharmacists need to know about migraine treatment and their role in educating and managing patients.

Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.

Advice to community pharmacists and patients who suffer from migraine on strategies that can improve quality of life and be used to navigate the care continuum.